Rafa Laboratories lands $186 million BARDA contract to develop life-saving trauma drug
Landmark studies have shown that rapid TXA administration can significantly reduce mortality
Landmark studies have shown that rapid TXA administration can significantly reduce mortality
The approvals target adult MIBC patients who are ineligible for cisplatin-based chemotherapy
HER2-mutant NSCLC typically has a poor prognosis and limited treatment options
The full approval is based on the results from the pivotal Phase 3 EPCORE FL-1 study
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
These initiatives will harness top scientific talent and advanced AI technologies to develop new ways to slow the rise of drug-resistant infections
The collaboration to develop breakthrough myeloid cell engagers (MCEs) signals a bold push into a promising new frontier in cancer therapy
The formulation is backed by over 80 clinical trials and 200 scientific publications
The 2025 edition of the EdelGive Hurun list recognizes 24 exceptional women leaders for their philanthropic impact across critical areas
Subscribe To Our Newsletter & Stay Updated